MODIFIED INTERFERON-ALPHA-2 HAVING REDUCED IMMUNOGENICITY
The present disclosure is directed to compositions comprising modified interferon-α2 polypeptides having interferon-α2 activity and reduced immunogenicity. In aspects, said modified interferon-α2 polypeptides are hyperglycosylated, such as by addition of a GM-CSF-derived peptide sequence with multiple O-glycosylation sites. Furthermore, the present disclosure provides compositions comprising a nucleic acid molecule encoding said modified interferon-α2. The present disclosure also provides compositions comprising a recombinant protein expression cell line comprising said nucleic acid molecule encoding said modified interferon-α2; wherein said recombinant protein expression cell comprises a plasmid or vector containing said nucleic acid molecule. Also disclosed are pharmaceutical compositions comprising a modified interferon-α2 having interferon-α2 activity with reduced immunogenicity, as well as methods of use of said pharmaceutical formulations for treatment of medical conditions in a subject.
1 - 108 . (canceled)
109 . A modified interferon-α2 polypeptide having interferon-α2 activity, the polypeptide comprising:
an amino acid sequence comprising at least 80% identity to SEQ ID NO: 12 and comprising one or more amino acid substitutions in any of the positions selected from the group consisting of: 9, 17, 47, 65, 66, 117, 123, 128, 147, and 157; wherein said substitution comprises the change of the amino acid of said position to alanine, glycine, or threonine; or
an amino acid sequence with at least 80% homology to SEQ ID NO: 10 and comprising one or more amino acid substitutions in any of the positions selected from the group consisting of: 23, 31, 61, 79, 80, 131, 137, 142, 161, and 171; wherein said substitution comprises the change of the amino acid of said position to alanine, glycine, or threonine; or
wherein the polypeptide comprises an amino acid sequence with at least 80% homology to SEQ ID NO: 22 and comprising at least five amino acid substitutions in any of the positions selected from the group consisting of: 9, 17, 47, 65, 66, 117, 123, 128, 147, and 157; wherein said substitution comprises the change of the amino acid of said position to alanine, glycine, or threonine; or
wherein the polypeptide comprises an amino acid sequence with at least 80% homology to SEQ ID NO: 21 and comprising at least five amino acid substitutions in any of the positions selected from the group consisting of: 23, 31, 61, 79, 80, 131, 137, 142, 161, and 171; wherein said substitution comprises the change of the amino acid of said position to alanine, glycine, or threonine; or
wherein the polypeptide comprises an amino acid sequence with at least 80% homology to SEQ ID NO: 24 and comprising at least five amino acid substitutions in any of the positions selected from the group consisting of: 9, 17, 47, 65, 66, 117, 123, 128, 147, and 157; wherein said substitution comprises the change of the amino acid of said position to alanine, glycine, or threonine;
wherein the polypeptide comprises an amino acid sequence with at least 80% homology to SEQ ID NO: 23 and comprising at least five amino acid substitutions in any of the positions selected from the group consisting of: 23, 31, 61, 79, 80, 131, 137, 142, 161, and 171; wherein said substitution comprises the change of the amino acid of said position to alanine, glycine, or threonine;
a nucleic acid encoding any one of said polypeptides;
a plasmid encoding any one of said polypeptides;
a vector comprising a nucleic acid encoding any one of said polypeptides;
a cell line comprising a nucleic acid encoding any one of said polypeptides;
or a pharmaceutical composition comprising any one of said polypeptides.
110 . The modified interferon-α2 polypeptide of claim 109 , wherein the polypeptide has a percentage antiproliferative biological activity of less than 5%.
111 . The modified interferon-α2 polypeptide of claim 109 , wherein the polypeptide has an apparent plasma clearance rate (Cl app ) of less than 115 mL/h.
112 . The modified interferon-α2 polypeptide of claim 109 , wherein the polypeptide is hyperglycosylated.
113 . The modified interferon-α2 polypeptide of claim 109 , wherein said polypeptide comprises the amino acid sequence comprising at least 80% identity to SEQ ID NO: 12 and comprising mutations: L9A, F47A, L117A, F123A, and L128A.
114 . The modified interferon-α2 polypeptide of claim 109 further comprising mutations:
I147T and L157A;
N65A and L66A;
L17A, I147T, and L157A; or
combinations thereof.
115 . The modified interferon-α2 polypeptide of claim 109 , wherein said polypeptide comprises the amino acid sequence with at least 80% homology to SEQ ID NO: 10 comprising mutations: L23A, F61A, L131A, F137A, and L142A.
116 . The modified interferon-α2 polypeptide of claim 115 further comprising mutations:
I161T and L171A;
N79A and L80A;
L31A, I161T, and L171A; or
combinations thereof.
117 . The modified interferon-α2 polypeptide of claim 109 , wherein said polypeptide comprises the amino acid sequence with at least 80% homology to SEQ ID NO: 22, comprising mutations L9A, F47A, L117A, F123A, and L128A.
118 . The modified interferon-α2 polypeptide of claim 117 , and further comprising mutations:
I147T and L157A;
N65A and L66A;
L17A, I147T, and L157A; or
combinations thereof.
119 . The modified interferon-α2 polypeptide of claim 109 , wherein said polypeptide comprises the amino acid sequence with at least 80% homology to SEQ ID NO: 21, comprising mutations L23A, F61A, L131A, F137A, and L142A.
120 . The modified interferon-α2 polypeptide of claim 119 further comprising mutations:
I161T and L171A;
N79A and L80A;
L31A, I161T, and L171A; or
combinations thereof.
121 . The modified interferon-α2 polypeptide of claim 109 , wherein said polypeptide comprises the amino acid sequence with at least 80% homology to SEQ ID NO: 24, comprising mutations L9A, F47A, L117A, F123A, and L128A.
122 . The modified interferon-α2 polypeptide of claim 121 further comprising mutations:
I147T and L157A;
N65A and L66A;
L17A, I147T, and L157A; or
combinations thereof.
123 . The modified interferon-α2 polypeptide of claim 109 , wherein said polypeptide comprises the amino acid sequence with at least 80% homology to SEQ ID NO: 23, comprising mutations L23A, F61A, L131A, F137A, and L142A.
124 . The modified interferon-α2 polypeptide of claim 123 further comprising mutations:
I161T and L171A;
N79A and L80A;
L31A, I161T, and L171A; or
combinations thereof.
125 . The modified interferon-α2 polypeptide of claim 109 , wherein
the polypeptide comprises the amino acid sequence with at least 80% homology to SEQ ID NO: 12 and the polypeptide has a reduced immunogenicity as compared to a wild type interferon-α2b polypeptide of SEQ ID NO: 12;
the polypeptide comprises the amino acid sequence with at least 80% homology to SEQ ID NO: 10 and the polypeptide has a reduced immunogenicity as compared to a wild type interferon-α2b polypeptide of SEQ ID NO: 10;
the polypeptide comprises the amino acid sequence with at least 80% homology to SEQ ID NO: 22 and the polypeptide has a reduced immunogenicity as compared to a wild type interferon-α2b polypeptide of SEQ ID NO: 22;
the polypeptide comprises the amino acid sequence with at least 80% homology to SEQ ID NO: 21 and the polypeptide has a reduced immunogenicity as compared to a wild type interferon-α2b polypeptide of SEQ ID NO: 21;
the polypeptide comprises the amino acid sequence with at least 80% homology to SEQ ID NO: 24 and the polypeptide has a reduced immunogenicity as compared to a wild type interferon-α2b polypeptide of SEQ ID NO: 24; or
the polypeptide comprises the amino acid sequence with at least 80% homology to SEQ ID NO: 23 and the polypeptide has a reduced immunogenicity as compared to a wild type interferon-α2b polypeptide of SEQ ID NO: 23.
126 . The modified interferon-α2 polypeptide of claim 109 , wherein
the polypeptide comprises the amino acid sequence with at least 80% homology to SEQ ID NO: 12 and has a relative antiviral activity of between 5% and 95% as compared to a wild type interferon-α2b polypeptide of SEQ ID NO: 12;
the polypeptide comprises the amino acid sequence with at least 80% homology to SEQ ID NO: 10 and has a relative antiviral activity of between 5% and 95% as compared to a wild type interferon-α2b polypeptide of SEQ ID NO: 10;
the polypeptide comprises the amino acid sequence with at least 80% homology to SEQ ID NO: 22 and has a relative antiviral activity of between 5% and 95% as compared to a wild type interferon-α2b polypeptide of SEQ ID NO: 22;
the polypeptide comprises the amino acid sequence with at least 80% homology to SEQ ID NO: 21 and has a relative antiviral activity of between 5% and 95% as compared to a wild type interferon-α2b polypeptide of SEQ ID NO: 21;
the polypeptide comprises the amino acid sequence with at least 80% homology to SEQ ID NO: 24 and has a relative antiviral activity of between 5% and 95% as compared to a wild type interferon-α2b polypeptide of SEQ ID NO: 24; or
the polypeptide comprises the amino acid sequence with at least 80% homology to SEQ ID NO: 23 and has a relative antiviral activity of between 5% and 95% as compared to a wild type interferon-α2b polypeptide of SEQ ID NO: 23.
127 . The polypeptide of claim 109 at a therapeutically effective amount and in a pharmaceutical composition configured for administration to a subject.
128 . A method of treating one or more diseases in a subject, comprising administering to the subject one or more of the modified interferon-α2 polypeptides of claim 109 , wherein said disease is selected from the group consisting of melanomas (including malignant melanoma), chronic hepatitis C (including in patients with compensated liver disease), acute and chronic hepatitis B, acute and chronic non-A, non-B hepatitis, Kaposi's sarcoma (including AIDS-related Kaposi's sarcoma), multiple sclerosis, genital warts, leukemia (including Hairy cell leukemia), lymphomas (including follicular lymphoma), condylomata acumiate, SARS-CoV-2 infection, ZIKV infection, CHIKV infection, and influenza A infection.
129 . A method of isolating the polypeptide of claim 109 comprising:
contacting a sample with an antibody using immunoaffinity chromatography, wherein said antibody comprises an anti-nonglycosylated rhIFN-α2b mAb CA5E6 antibody, an anti-hGM-CSF monoclonal antibody, or both.